Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 9—September 2009
Research

Susceptibilities of Nonhuman Primates to Chronic Wasting Disease

Brent Race1Comments to Author , Kimberly D. Meade-White1, Michael W. Miller, Kent D. Barbian, Richard Rubenstein, Giuseppe LaFauci, Larisa Cervenakova, Cynthia Favara, Donald Gardner, Dan Long, Michael Parnell, James Striebel, Suzette A. Priola, Anne Ward, Elizabeth S. Williams2, Richard Race3, and Bruce Chesebro3
Author affiliations: Rocky Mountain Laboratories, Hamilton, Montana, USA (B. Race, K.D. Meade-White, K.D. Barbian, C. Favara, D. Gardner, D. Long, M. Parnell, J. Striebel, S.A. Priola, A. Ward, R. Race, B. Chesebro); Colorado Division of Wildlife, Fort Collins, Colorado, USA (M.W. Miller); State University of New York Downstate Medical Center, Brooklyn, New York, USA (R. Rubenstein); New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, USA (G. LaFauci); American Red Cross, Rockville, Maryland, USA (L. Cervenakova); University of Wyoming, Laramie, Wyoming, USA (E.S. Williams)

Main Article

Table 2

Results of squirrel monkey oral inoculation with CWD agent*

Monkey no. PrP genotype† CWD inoculum Titer inoculated‡ Incubation period, mpi§ Weight change, %
303¶ NT MD-1 1.5 × 109 69 –25
360 A MD-1 1.5 × 109 NS (69) +6
588 C MD-3 9.6 × 107 NS (52) +5
629 B MD-3 9.6 × 107 NS (52) 0
631 A Elk-1 1.9 × 108 NS (52) 0
335 NT Elk-2 6.0 × 108 NS (69) –5
656 B Elk-2 6.0 × 108 NS (52) –5
614# A Elk-2 6.0 × 108 44 –10
317 C Elk-3 3.9 × 108 NS (69) 0
301** NT Elk-3 3.9 × 108 39 –14
307 A WTD-1 1.2 × 109 NS (69) +8
345†† A WTD-1 1.2 × 109 69 –33
626 NT WTD-2 1.9 × 108 NS (52) +11
641 B WTD-2 1.9 × 108 NS (52) 0
325 NT WTD-2 1.9 × 108 NS (69) –8
655 A Buffer control NS (52) –6
314 NT Normal elk NS (69) +7

*CWD, chronic wasting disease; PrP, prion protein; mpi, months postinfection; NT, not tested (sequenced); NS, no signs.
†See Table 4 for a description of genotypes A, B, and C.
‡Infectivity titers were determined by using endpoint dilution titer in transgenic deer expressing mouse PrP and are listed as the 50% infectious dose/g of brain administered over 5 d at 2–6-d intervals.
§Incubation periods for monkeys with clinical wasting are indicated as mpi in parentheses. NS indicates that these monkeys did not show any clinical signs compatible with transmissible spongiform encephalopathy (TSE) or wasting.
¶Monkey 303 was euthanized at 69 mpi because of signs of wasting, weakness, and anorexia.
#Monkey 614 was euthanized at 44 mpi because of complications arising from anesthesia for routine tuberculosis testing. No signs of TSE were observed before the complications, and Western blot and immunohistochemical results showed that this monkey was negative for protease-resistant PrP (PrPres).
**Monkey 301 was euthanized at 39 mpi after a brief illness with signs of lethargy, anorexia, and dehydration. PrPres was detected in peripheral lymphoid tissues but not in brain.
††Monkey 345 was found dead at 69 mpi. Brain, spleen, and lymph nodes were positive for PrPres by Western blot.

Main Article

1These authors contributed equally to this article.

2Deceased.

3Co-senior authors.

Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external